معرفی
Professor Thomas Milne is a leading researcher in epigenetic control of gene expression in leukaemia and haematopoiesis at the University of Oxford's Radcliffe Department of Medicine. He directs the Milne Group at the MRC Weatherall Institute of Molecular Medicine and the MRC Molecular Haematology Unit, focusing on chromatin biology in high-risk paediatric leukaemias, particularly those caused by MLL gene rearrangements.
His research explores how chromatin proteins contribute to gene regulation in normal haematopoietic cells and disease states, with emphasis on enhancer activity and its role in leukaemogenesis. The lab employs cutting-edge techniques including ATAC-seq, ChIP-seq, Capture C, and nascent RNA-seq to investigate epigenetic mechanisms and identify novel therapeutic targets for currently incurable leukaemias.
Recent publications demonstrate his team's focus on MLL-AF4 leukemia mechanisms, enhancer heterogeneity, CD133 as a therapeutic target, and the development of novel models for high-risk paediatric leukaemias. His work bridges fundamental epigenetic mechanisms with translational applications, aiming to develop targeted combination therapies for leukaemia patients.
Professor Milne leads a collaborative research team including postdoctoral researchers, DPhil students, and maintains long-term collaborations with the Roberts and Roy labs. His lab has secured funding from the Medical Research Council and is developing a spinout company, Dark Blue Therapeutics, to translate research findings into clinical applications.